Silexion Therapeutics appointed Avner Lushi to its audit committee following the resignation of Professor Peled on August 1, 2026. This appointment restores the company's compliance with Nasdaq's governance requirements and reflects a commitment to strong corporate oversight, which could reassure investors about its governance practices going forward.
Key Highlights
- Professor Peled's resignation was effective August 1, 2026, due to personal reasons without disagreements.
- Avner Lushi has served on Silexion's board since August 2024 and has extensive board experience across public companies.
- The appointment reinstates the audit committee's compliance with Nasdaq Listing Rules, requiring three independent members.
- The audit committee now consists of Dror J. Abramov, Ruth Alon, and Avner Lushi as independent members.
Silexion Therapeutics has appointed Avner Lushi to its audit committee, effectively filling the vacancy left by Professor Peled's resignation, which took effect on August 1, 2026. Professor Peled stepped down for personal reasons, clarifying that the decision was not due to any disagreements over the company's operations or policies. Lushi, an independent board member since August 2024, is well-regarded for his extensive experience, which positions him to enhance the audit committee's oversight capabilities.
This leadership change marks a notable moment for the company as it seeks to uphold its governance standards amid personnel shifts.
Audit Committee Structure Restored
The company’s audit committee now comprises three independent members, adhering to Nasdaq Listing Rule 5605’s composition requirements. These members include Dror J. Abramov, Ruth Alon, and Avner Lushi, demonstrating Silexion’s commitment to sound corporate governance practices. His legal and economic background further enhances the committee’s ability to navigate complex financial oversight.
This restoration not only complies with regulatory standards but also signals to investors that the company prioritizes strong governance.
Timely Response to Governance Needs
Silexion's move to appoint an experienced board member now reflects an immediate response to regulatory and operational necessities. It also reinforces the company's commitment to transparency and accountability in its financial reporting and operations. Adhering to the Nasdaq Listing Rules is important for maintaining investor trust and market credibility, especially in an environment where governance standards are under intense scrutiny.
Each appointee’s independent status safeguards against potential conflicts of interest, an essential characteristic in maintaining investor confidence, particularly among those tracking governance metrics closely.
Looking Ahead: Future Compliance and Meetings
As Silexion Therapeutics continues to advance its corporate governance efforts, the upcoming quarterly report will be critical in assessing the effectiveness of its governance structure. Investors will be keen to observe how Mr. Lushi’s appointment impacts the company's financial oversight and strategic direction. The company’s forthcoming annual meetings could further delineate its goals for regulatory compliance, transparency, and stakeholder engagement.
Stakeholders will closely monitor these developments to understand how leadership changes translate into operational performance and market positioning.
Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...